Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	449
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	441
Bimekizumab for the Treatment of Psoriasis	321
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	316
Targeting DNA Damage Response Deficiency in Thoracic Cancers	227
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	190
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	173
Aprocitentan: First Approval	158
Eftrenonacog Alfa: A Review in Haemophilia B	137
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	134
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	127
Epcoritamab: First Approval	126
Spesolimab for the Treatment of Generalized Pustular Psoriasis	121
Teclistamab: First Approval	117
Vorasidenib: First Approval	116
New Therapies on the Horizon for Primary Biliary Cholangitis	111
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	108
Senaparib: First Approval	107
Cosibelimab: First Approval	106
Upacicalcet: First Approval	106
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	104
Repotrectinib: First Approval	103
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	96
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	96
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	94

Olipudase Alfa: First Approval	93
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	92
Ivarmacitinib Sulfate: First Approval	92
Atogepant: First Approval	92
Drugs in Development to Manage Acute Pain	90
Lenacapavir: First Approval	86
Danicopan: First Approval	83
Finerenone: First Approval	82
Acoltremon: First Approval	82
Androgenetic Alopecia: Therapy Update	82
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	82
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	81
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	80
Cancer Pain Treatment Strategies in Patients with Cancer	77
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	75
Mosunetuzumab: First Approval	73
Olverembatinib: First Approval	73
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	73
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	72
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	72
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	70
Correction to: Tapinarof Cream 1%: First Approval	70
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	67
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	67
Correction to: Prevention and Treatment of Monkeypox	66
The Place of Cannabinoids in the Treatment of Gynecological Pain	65
Tovorafenib: First Approval	65
Dorzagliatin: First Approval	65
Sunvozertinib: First Approval	64
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	64
Pozelimab: First Approval	62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	60
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	59
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	59
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	57
Birch Bark Extract: A Review in Epidermolysis Bullosa	55
Correction to: Concizumab: First Approval	55
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	54
Ozoralizumab: First Approval	54
Tirzepatide: A Review in Type 2 Diabetes	54
Gepirone Extended-Release: First Approval	54
Asciminib: First Approval	54
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	54
Correction to: Remdesivir: A Review in COVID-19	53
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	53
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	53

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	52
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	51
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	50
Disitamab Vedotin: First Approval	50
Aumolertinib: A Review in Non-Small Cell Lung Cancer	50
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	50
Catumaxomab: First Approval	50
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	49
Givinostat: First Approval	49
Correction to: Sotorasib: First Approval	48
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	48
Correction: Teprotumumab: A Review in Thyroid Eye Disease	47
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	46
Futibatinib: First Approval	46
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	46
Ensitrelvir Fumaric Acid: First Approval	46
Fezolinetant: First Approval	46
Avacincaptad Pegol: First Approval	43
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	43
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	43
Zastaprazan: First Approval	42
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	42
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	42
Tisotumab Vedotin: First Approval	42
Eye Involvement and Management in Inherited Epidermolysis Bullosa	41
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	41
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	41
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	41
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	40
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	40
Correction: Iptacopan: First Approval	38
Beremagene Geperpavec: First Approval	38
Gastrointestinal Dysfunction in Parkinson’s Disease	38
Lotilaner Ophthalmic Solution 0.25%: First Approval	38
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	38
Savolitinib: First Approval	36
Imetelstat: First Approval	36
Imeglimin Hydrochloride: First Approval	36
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	36
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	36
Tebentafusp: First Approval	35
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	35
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	34
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	34
Acknowledgement to Referees	34
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	34
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	33
Crinecerfont: First Approval	33
Avatrombopag: A Review in Thrombocytopenia	33
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	33
Revumenib: First Approval	32
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	32
Nogapendekin alfa Inbakicept: First Approval	32
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	32
Mavorixafor: First Approval	31
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	31
Retifanlimab: First Approval	31
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	31
Correction to: Abrocitinib: First Approval	30
Donafenib: First Approval	30
Correction to: Sparsentan: First Approval	30
Diagnosis and Treatment of AL Amyloidosis	30
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	30
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	29
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	29
Keverprazan Hydrochloride: First Approval	28
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Correction: Zastaprazan: First Approval	28
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	28
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	27
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Correction to: Spesolimab: First Approval	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Zolbetuximab: First Approval	27
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Antibacterials with Novel Chemical Scaffolds in Clinical Development	26
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	26
Remdesivir: A Review in COVID-19	26
Daridorexant: First Approval	26

Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	26
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	26
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Gefapixant: First Approval	25
Regdanvimab: First Approval	25
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	25
Molnupiravir: First Approval	25
Spesolimab: First Approval	25
Marstacimab: First Approval	25
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	25
Elranatamab: First Approval	25
Lecanemab: First Approval	24
Odevixibat: First Approval	24
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	24
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	24
Abrocitinib: First Approval	24
Correction to: Rozanolixizumab: First Approval	23
Pucotenlimab: First Approval	23
Amubarvimab/Romlusevimab: First Approval	23
Comment on: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	23
Tixagevimab + Cilgavimab: First Approval	23
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	23
Nadofaragene Firadenovec: First Approval	23
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	23
Correction to: Mavacamten: First Approval	23
Chiglitazar: First Approval	22
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	22
Correction to: Contezolid: First Approval	22
New Developments in Glucagon Treatment for Hypoglycemia	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Tofersen: First Approval	22
Acknowledgement to Referees	22
Correction to: Ozanimod: A Review in Ulcerative Colitis	22
Ritlecitinib: First Approval	22
Valoctocogene Roxaparvovec: First Approval	21
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	21
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	21
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	21
Talquetamab: First Approval	21
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	21
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer	21
Furmonertinib: First Approval	21
Eplontersen: First Approval	21
Differentiating IL-23 Inhibitors in Crohn’s Disease	21
Elafibranor: First Approval	20
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	20
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	20
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	20
Sipavibart: First Approval	19
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	19
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	19
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	19
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	19
Iptacopan: First Approval	18
Dimdazenil: First Approval	18
Sotorasib: First Approval	18
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	18
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	18
Mirvetuximab Soravtansine: First Approval	18
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	18
Sulbactam/Durlobactam: First Approval	18
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective	18
Vosoritide: First Approval	18
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	17
Vamorolone: First Approval	17
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	17
Motixafortide: First Approval	17
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	17
Tunlametinib: First Approval	17
Tirzepatide: First Approval	17
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	16
Drug-Induced Pigmentation: A Review	16
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	16
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	16
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	16
Fitusiran: First Approval	16
Nemolizumab: First Approval	16
Linzagolix: First Approval	16
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	16
Vimseltinib: First Approval	16
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	16
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	16
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	16
Results from Expanded Access Programs: A Review of Academic Literature	16
Correction to: Daridorexant: First Approval	15
Tegileridine: First Approval	15
Rezvilutamide: First Approval	15
Drugs in Development to Treat IgA Nephropathy	15
The Potential of RNA Therapeutics in Treating Cardiovascular Disease	15
Ebronucimab: First Approval	15
Anticoagulation in Chronic Kidney Disease	15
Current and Emerging Therapies for Lysosomal Storage Disorders	14
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	14